MediXall (MDXL) Cash & Equivalents (2019 - 2024)
MediXall's Cash & Equivalents history spans 8 years, with the latest figure at $31916.0 for Q3 2024.
- For Q3 2024, Cash & Equivalents rose 230.15% year-over-year to $31916.0; the TTM value through Sep 2024 reached $31916.0, up 230.15%, while the annual FY2023 figure was $10721.0, 213.85% up from the prior year.
- Cash & Equivalents reached $31916.0 in Q3 2024 per MDXL's latest filing, down from $32621.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $1.3 million in Q1 2021 to a low of $2289.0 in Q1 2023.
- Average Cash & Equivalents over 5 years is $224293.1, with a median of $75578.0 recorded in 2022.
- Peak YoY movement for Cash & Equivalents: crashed 97.8% in 2023, then surged 2250.94% in 2024.
- A 5-year view of Cash & Equivalents shows it stood at $645762.0 in 2020, then tumbled by 90.18% to $63418.0 in 2021, then tumbled by 94.61% to $3416.0 in 2022, then soared by 213.85% to $10721.0 in 2023, then skyrocketed by 197.7% to $31916.0 in 2024.
- Per Business Quant, the three most recent readings for MDXL's Cash & Equivalents are $31916.0 (Q3 2024), $32621.0 (Q2 2024), and $53813.0 (Q1 2024).